Patterns of Care and Outcomes of Adjuvant Chemoradiation for Node-Positive Pancreatic Adenocarcinoma

Author(s):  
A. Lee ◽  
N. Malakhov ◽  
A.A. Albert ◽  
A.J. Lederman ◽  
J. Safdieh ◽  
...  
2019 ◽  
Vol 51 (2) ◽  
pp. 506-514
Author(s):  
Nikita Malakhov ◽  
Anna Lee ◽  
Ashley Albert ◽  
Ariel Lederman ◽  
John Byun ◽  
...  

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 347-347 ◽  
Author(s):  
Mustafa Raoof ◽  
Laleh Golkar Melstrom ◽  
Susanne Warner ◽  
Yanghee Woo ◽  
Gagandeep Singh ◽  
...  

347 Background: American Society of Clinical Oncology guidelines recommend adjuvant chemoradiation (ACR) for margin-positive(R1) and/or node-positive (N+) pancreatic cancers. However, randomized trials and meta-analyses have have not shown superiority of ACR over AC. Methods: National Cancer Database (NCDB) was used to analyze patients with N+ and/or R1 pancreatic adenocarcinoma who underwent ACR or AC over a ten-year period (2004-2014). Patients who received neoadjuvant radiation, no adjuvant treatment or adjuvant radiation alone were excluded. Propensity score nearest-neighbor 1:1 matching (PSM) was performed between ACR and AC groups based on age, sex, race, insurance, comorbidities, T-stage, nodal status, margin status, grade, and neoadjuvant chemotherapy. Primary outcome was overall survival (OS). Results: A total of 9,732 patients were eligible. After PSM two well-balanced groups of 4000 patients each were analyzed. ACR resulted in superior OS in patients with N+ and/or R1 disease as compared to AC alone (HR: 0.83, 95% CI 0.78-0.87; Median OS 22 vs. 19 months, p<0.001). Subset analyses demonstrated overall survival benefit of ACR compared to AC in N+, margin-negative patients (HR: 0.82, 95% CI 0.77-0.88; Median OS 24 vs. 20 months, p<0.001), as well as N+, R1 patients (HR: 0.77, 95% CI 0.68-0.87; Median OS 17 vs. 15 months, p<0.001); but no benefit in node-negative, R1 patients (HR: 1.12, 95% CI 0.84-1.48; Median OS 18 vs. 22 months, p = 0.43). Conclusions: This is the largest study to date that shows superiority of ACR over AC in N+ patients irrespective of margin status. The study failed to show a survival benefit in R1, node-negative patients.


2015 ◽  
Vol 46 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Andrew M. McDonald ◽  
Caleb R. Dulaney ◽  
Javier López-Araujo ◽  
James A. Posey ◽  
Kimberly S. Keene ◽  
...  

2009 ◽  
Vol 13 (9) ◽  
pp. 1699-1706 ◽  
Author(s):  
Dong Do You ◽  
Hyung Geun Lee ◽  
Jin Seok Heo ◽  
Seong Ho Choi ◽  
Dong Wook Choi

Author(s):  
Jason K. Molitoris ◽  
Tejan Diwanji ◽  
James W. Snider ◽  
Emily C. Bellavance ◽  
Susan B. Kesmodel ◽  
...  

2011 ◽  
Vol 80 (5) ◽  
pp. 1391-1397 ◽  
Author(s):  
David P. Horowitz ◽  
Charles C. Hsu ◽  
Jingya Wang ◽  
Martin A. Makary ◽  
Jordan M. Winter ◽  
...  

2016 ◽  
Vol 151 (6) ◽  
pp. 1549-1558.e2 ◽  
Author(s):  
Matthew J. Bott ◽  
Aalok P. Patel ◽  
Vivek Verma ◽  
Traves D. Crabtree ◽  
Daniel Morgensztern ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document